#Cambridge #United Kingdom #Biofidelity #CellCarta #Aspyre Lung

Biofidelity and CellCarta's Groundbreaking Partnership

In an exciting development for the field of oncology, Biofidelity, a pioneer in genomic solutions, has partnered with CellCarta, a leading contract research organization (CRO), to deploy their innovative product, Aspyre® Lung, in global clinical trials. This strategic collaboration aims to enhance the efficiency and accuracy of cancer diagnosis, particularly focusing on non-small cell lung cancer (NSCLC).

Innovating Cancer Detection

Aspyre Lung is designed to simplify the detection of NSCLC biomarkers utilizing a streamlined workflow that involves analyzing DNA and RNA from both tissue and blood samples. Its standardized four-step process allows it to seamlessly integrate into existing quantitative polymerase chain reaction (qPCR) platforms, making it an accessible tool for laboratories worldwide.

Both companies are enthusiastic about the potential of this partnership to facilitate rapid enrollment in clinical trials, an aspect that is crucial for advancing cancer research and treatment. The collaboration leverages both liquid and tissue biopsy samples, providing innovative genomic services that are expected to accelerate clinical trial timelines significantly.

A Step Towards Global Implementation

The initial phase of the partnership will see CellCarta establishing and validating the Aspyre Lung technology in its European laboratories. Following this introduction, the implementation will extend to its laboratories in the United States. Importantly, CellCarta has obtained non-exclusive rights to utilize Aspyre Lung for clinical trials across the globe, enhancing its capabilities in delivering tailored solutions to biopharmaceutical clients.

Barnaby Balmforth, Ph.D., the co-founder and CEO of Biofidelity, expressed his excitement regarding the partnership, noting that they are committed to expanding access to genomic technologies that can transform patient care worldwide. He believes that by integrating Aspyre Lung into clinical settings, they can significantly streamline the enrollment process for clinical trials while providing patients with cutting-edge diagnostic tools.

Enhancing Precision Medicine

Dusty Tenney, CEO of CellCarta, also shared his enthusiasm about this partnership. He emphasized that CellCarta's extensive portfolio of biomarker testing services positions the company well to integrate Aspyre Lung. This addition aligns perfectly with their mission of promoting precision medicine through specialized laboratory services that meet the unique demands of the pharmaceutical and biotech industries.

The Future of Cancer Diagnosis

This collaboration marks a significant advancement in the field of precision medicine. As genomic profiling continues to evolve, tools like Aspyre Lung will play an increasingly vital role in diagnosing and monitoring cancer. With the promise of greater accuracy, speed, and accessibility in clinical trials, these innovative services may lead to life-saving breakthroughs for patients.

For more detailed information about Biofidelity’s offerings or to explore CellCarta’s capabilities, interested parties can visit their respective websites. This partnership promises not only to drive innovation in clinical trials but also to pave the way for advancements in cancer treatment and patient management globally.